Rate Video

ASH 2018 | AML highlights from ASH 2018

Guillermo Garcia-Manero

Acute Myeloid Leukemia Leukemia Antibodies Checkpoint inhibitors Pracinostat Venetoclax

Guillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, delivers key highlights, including exciting trials, future outlooks, and developments in the field of acute myeloid leukemia (AML) from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

MRD Focus: why measurable residual disease testing is the future

Bruno Paiva et al.

May the force be with you: the power of next-generation sequencing

Guillermo Garcia-Manero • 9 Dec 2017

The association between mutations and comorbidities in patients with MDS

Guillermo Garcia-Manero • 10 Jun 2022

An update on ASTRAL-3: guadecitabine vs treatment of choice in adults with previously treated MDS

Guillermo Garcia-Manero • 10 Jun 2022

Related Videos

Current standard of care in BPDCN

Uwe Platzbecker • 21 Jun 2022

Dose-adjusted EPOCH plus inotuzumab ozogamicin for B-ALL

Ryan Cassaday • 20 Jun 2022

Updated PFS results of the GAIA/CLL13 trial

Barbara Eichhorst • 20 Jun 2022

The benefits of next-generation BTK inhibitors in CLL

Barbara Eichhorst • 20 Jun 2022